Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Older donor age is not associated with inferior survival in contemporary haploidentical transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

YAYosra AljawaiDMDenái R. MiltonRMRohtesh S. Mehta

Discussion

Loading...

Member takes

Overview

Observational analysis shows donor age is linked to graft-versus-host disease risk but not overall survival in patients undergoing haploidentical transplantation.

Key Points

  • To examine the effect of donor age on survival outcomes in haploidentical hematopoietic stem cell transplant recipients.
  • Included 364 adult patients with hematologic malignancies who underwent HCT with haploidentical donors
  • Analyzed overall survival (OS) and progression-free survival (PFS) based on donor age categorization
  • Utilized post-transplant cyclophosphamide-based GVHD prophylaxis
  • No significant donor age cutoff associated with OS or PFS was identified
  • Older donor age linked to increased risk of severe acute GVHD
  • Relapse rates were lower in older donor age groups compared to younger donors

Cite This Study

Aljawai et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfb3https://doi.org/10.1182/blood-2025-168
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC2025 · 1 citations
  2. 2Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis2025
  3. 3Donor Age ≥30 Years as an Independent Predictor of Inferior Outcomes After Haploidentical Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Study Conducted on Behalf of GETH-TC2025
  4. 4Differentiating donor age on AML patient outcomes in the post-transplant cyclophosphamide contemporary era.2026
  5. 5Old mismatched donors are associated with inferior outcomes after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome, but not in Acute Myeloid Leukemia2025